Immuneering (IMRX) Retained Earnings (2020 - 2026)
Immuneering (IMRX) recorded quarterly Retained Earnings of -$293.8 million in Q1 2026, down 4.8% quarter-over-quarter from -$280.3 million in Q4 2025, and down 22.75% on a YoY basis from -$380.3 million in Q1 2025.
Immuneering (IMRX) Retained Earnings (2020 - 2026) Analysis & Trends
Immuneering's Retained Earnings history runs 7 years deep, the most recent figure standing at -$293.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 22.75% year-over-year to -$293.8 million; the TTM figure through Mar 2026 stood at -$293.8 million (down 22.75% YoY), while the FY2025 annual figure was -$280.3 million, changed N/A from the prior year.
- Retained Earnings was -$293.8 million for Q1 2026 at Immuneering, down from -$280.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $5607.0 in Q3 2023 to a low of -$293.8 million in Q1 2026.
- Historically, Retained Earnings has averaged -$108.4 million across 5 years, with a median of -$167395.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings soared 103.94% in 2023, then sank 22079357.38% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$30120.0 in 2022, then soared by 97.42% to -$778.0 in 2023, then tumbled by 26503756.04% to -$206.2 million in 2024, then slumped by 35.95% to -$280.3 million in 2025, then slipped by 4.8% to -$293.8 million in 2026.
- The last three Retained Earnings figures came in at -$293.8 million (Q1 2026), -$280.3 million (Q4 2025), and -$268.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | -293.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -293.78 Mn |
| Dec 31, 2025 | -280.32 Mn |
| Sep 30, 2025 | -268.74 Mn |
| Jun 30, 2025 | -253.78 Mn |
| Mar 31, 2025 | -239.34 Mn |
| Sep 30, 2024 | -206.20 Mn |
| Mar 31, 2024 | -1,084.00 |
| Dec 31, 2023 | -778.00 |
| Sep 30, 2023 | 5,607.00 |
| Jun 30, 2023 | -2,218.00 |
| Mar 31, 2023 | 506.00 |
| Dec 31, 2022 | -30,120.00 |
| Sep 30, 2022 | -142,473.00 |
| Jun 30, 2022 | -83.70 Mn |
| Mar 31, 2022 | -167,395.00 |
| Dec 31, 2021 | -59.27 Mn |
| Sep 30, 2021 | -48.49 Mn |
| Jun 30, 2021 | -39.95 Mn |
| Dec 31, 2020 | -25.74 Mn |